Background: The Global Anticoagulant Registry in the FIELDeAtrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed nonvalvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. Methods and results: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012e2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3e2.3) versus 2.3 (IQR 1.8e2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32e9.35) vs 4.34 (4.16e4.53), P < 0.0001], while rates of stroke/ systemic embolism and major bleeding were lower after 1 year of follow-up. Conclusion: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. Clinical trial registrationdURL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia worldwide, 1 with a prevalence of 1e2% in the general population.
AF is an important contributor to all-cause mortality, cognitive decline, and stroke. The likelihood of nonvalvular AF (NVAF) increases with advancing age and is often accompanied by the presence of diabetes and cardiovascular comorbidities, such as heart failure and coronary artery disease (CAD). In the recently published Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF) registry from India, the most common underlying cardiovascular risk factors in patients with AF were hypertension (50.8%) and diabetes (20.4%) . In addition, a high proportion of patients had a history of valvular heart disease (40.7%). 2, 3 India has over 1.2 billion inhabitants 4 and is undergoing remarkable economic changes in the recent years and is making important inroads into improving cardiovascular health care despite finite resources. By the year 2050, however, the aging population (60e80 years) is projected to increase by 326% and for patients 80 years, by 700%. 5 As aging is a risk factor for AF, this change, along with other age-associated cardiovascular disease, is likely to add to already high index levels of AF associated with rheumatic heart disease. 6, 7 To date, most of our understanding of NVAF is based on observational studies from North America and western Europe. 8 Recently published registry data from the Indian Heart Rhythm Society (IHRS-AF) registry 9 ; Randomised Evaluation of Long-Term Anticoagulation Therapy registry 10 ; and REALISE-AF registry 2,3 have described patients with rheumatic valvular heart disease (RVHD) as well as those with NVAF. Global Anticoagulant Registry in the FIELDeAtrial Fibrillation (GARFIELD-AF) 11 is one of the first studies to evaluate patients with only NVAF in Indiadthereby allowing a comparison of similar patients from the rest of the world. Patients in the GARFIELD-AF were enrolled from 35 countries between 2010 and 2016 and are currently being followed up until 2018 when all patients will have had a minimum follow-up of 2 years and up to 8 years. This article describes the trends in stroke prevention treatment and records the burden of disease and one-year outcomes associated with NVAF in India.
Methods

Study design
The GARFIELD-AF is an ongoing prospective noninterventional disease registry of patients with newly diagnosed, predominantly NVAF (ClinicalTrials.gov Identifier: NCT01090362). 11 Patients were enrolled into the GARFIELD-AF registry from over 1000 centers in 35 countries worldwide, from America, Europe, Africa, and Asia. Eligible patients included men and women aged 18 years with NVAF, diagnosed according to standard local procedures within the previous 6 weeks and with at least one additional risk factor for stroke. Risk factors were neither prespecified in the protocol nor were they limited to the components of existing risk stratification schemes. The registry excluded patients with a transient reversible cause of AF and those for whom follow-up was not envisaged or possible. Investigator sites were selected randomly and represented the different care settings in each participating country (office-based practice; hospital departmentsdneurology, cardiology, geriatrics, internal medicine, and emergencydanticoagulation clinics; and general or family practice).
Ethics statement
All patients provided written informed consent to participate. Independent ethics committee and hospital-based institutional review board approvals were obtained, as necessary, for the registry protocol. The registry is being conducted in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on HarmonisationGood Pharmacoepidemiological and Clinical Practice Guidelines.
Procedures and outcomes measures
Baseline data collected at screening included patients characteristics, medical history, care setting, type of AF, date and method of diagnosis, symptoms, and anticoagulant (AC) treatment [vitamin K antagonists (VKAs), factor Xa inhibitors (FXas), and direct thrombin inhibitors (DTIs), as well as antiplatelet (AP) treatment]. Ethnicity was classified by the investigator in agreement with the patient.
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Data on all components of the CHA 2 DS 2 -VASc [congestive heart failure (CHF), hypertension, diabetes, vascular disease, age 65e74 years, and female gender, age 75 years and previous systemic embolism] 12 and the HAS-BLED 13 risk stratification schemes were collected to assess the risks of stroke and bleeding retrospectively. Vascular disease was defined as peripheral artery disease and/or CAD with a history of acute coronary syndrome. Hypertension was defined as a documented history of hypertension or blood pressure >140/90 mmHg at rest.
Data collection
GARFIELD-AF data were collected using an electronic case report form (eCRF) and captured by trained personnel. The eCRF was designed by Dendrite Clinical Systems Ltd, Henley-on-Thames, UK, the group which is also responsible for the ongoing database program manage- The GARFIELD-AF protocol requires that 20% of all eCRFs are monitored against source documentation, that there is an electronic audit trail for all data modifications, and that critical variables are subjected to additional audit. 14 
Statistical analysis
This article describes the baseline characteristics, treatment patterns, and 1-year outcomes based on global data and for patients recruited in India; data for these analyses were extracted from the registry database on 18th October 2017. Continuous variables are expressed as mean ± standard deviation (SD) and categorical variables as frequency and percentage. Use of antithrombotic therapy at baseline was analyzed by CHA 2 DS 2 -VASc and "modified" HAS-BLED (excluding fluctuations in the international normalized ratio) scores, calculated retrospectively from the data collected. Patients with missing values were not removed from the study.
Prothrombin time and international normalized ratio (INR) readings during the first year of follow-up were included in the analysis. Implausible INR values of less than 0.8 or greater than 20 were excluded. Patients on VKA treatment at enrollment, but with fewer than three readings during the follow-up, were excluded from the analysis. The distribution of INR values are described by counts and percentages below, within, and above the therapeutic range, and by the mean, SD, median, and interquartile range (IQR).
Occurrence of major clinical events (primarily, stroke/systemic embolism (SE), major bleeding, and all-cause mortality) is described using the number of events, the proportion of patients with the event divided by the population at risk at the beginning of the follow-up period, person-time event rate (per 100 personyears), and 95% confidence interval (CI). We estimated personyear rates using a Poisson model, with the number of events. Only the first occurrences of each event were taken into account. Data analysis was performed at the TRI with SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline patient characteristics
In total, 52,014 patients with a new diagnosis of AF were enrolled in the GARFIELD-AF between March 2010 and August 2016. Of these, 1388 of patients were from India recruited between August 2012 and August 2016 from 26 centers Fig. 1 . The mean (SD) time between enrollment and recruitment was 1.4 (1.5) weeks. The proportion of patients recruited by cohort is reported in Supplementary Figure S1 . Indian patients with NVAF in this registry were almost entirely diagnosed and managed by cardiologists (81.7%), with a small number of patients diagnosed by internal medicine (15.0%), neurology (1.2%), and primary care physicians (1.9%). Approximately nine of 10 patients were managed in the hospital setting (90.1%); a small number of patients were first attended to by emergency services (2.7%). Approximately 8% of the patients made use of private medical insurance for their care.
The baseline clinical characteristics of patients recruited in India and all countries are summarized in Table 1 . In India, majority (59.9%) of the patients were men; mean age at diagnosis of NVAF was 65.8 years, and 26.3% of the patients were 75 years. Hypertension was the most prevalent risk factor for AF, seen in 68.5% of patients from India and in 76.3% of patients globally. A lower body mass index (BMI) (average of 24.3 kg/m 2 ) was observed in patients from India compared with a global BMI average of 27.8 kg/m 2 (P < 0.001). Despite this, diabetes was prevalant in over a third of Indian patients (36.2%), a significantly higher proportion than patients globally (22.2%, P < 0.001). Cardiovascular comorbidities, such as CAD, were higher for patients from India than globally (28.1% vs 21.6%, P < 0.001) at the time of diagnosis of AF. Congestive heart failure (CHF) was Fig. 1 . GARFIELD-AF sites in India. GARFIELD-AF, Global Anticoagulant Registry in the FIELDeAtrial Fibrillation. prevalent in 15.5% of Indian patients and 20.0% of patients globally (P < 0.001). Nearly one-tenth of the patients had a history of transient ischaemic attack or prior stroke in India and all countries. In this registry of NVAF, a very low percentage of patients had RVHD globally (0.1%) and none from India. Prevalence of chronic kidney disease was 5.2% in India and 10.3% globally (P < 0.001).
The mean (±SD) CHA 2 DS 2 -VASc scores in India and all countries were 2.9 (1.5) and 3.2 (1.6), respectively (P < 0.001). Figure S2 in the Supplementary Material shows the distribution of patients across the range of CHA 2 DS 2 -VASc scores in India and all countries. Proportionately, there were more Indian patients with low stroke risk (CHAD 2 DS 2 -VASc 3). Approximately two-thirds of Indian patients (64.6%) had a new unclassified type of AF diagnosed. The most prevalent form of AF was paroxysmal AF (16.4%) in patients; followed by persistent (10.4%) and permanent AF (8.5%). In India and globally, antithrombotic therapy was prescribed to approximately 80% of the patients, whereas approximately 20% of the patients were not prescribed antithrombotic treatment. The most common antithrombotic treatment in India was AP therapy alone, in around 40% of the patients within each cohort. The most commonly prescribed oral AC for stroke prevention at diagnosis of AF was VKA ± AP therapy (in approximately 40% overall), and only few patients received Novel Oral Anticoagulant (NOAC) ± AP therapy (approximately 6%); this trend did not change appreciably over time in India. Fig. 3 shows the distribution of antithrombotic therapies according to the CHA 2 DS 2 -VASc scores. In India with increasing stroke risk, there was a marked increase in the proportions (from 20% to 50%) of patients receiving oral AC ± AP therapy and fewer patients receiving no therapy (from 31.6% to 6.8%). The proportions of patients receiving AP therapy alone remained consistent despite the increasing risk of stroke. Fig. 4 shows the HAS-BLED risk profile of patients in India and all countries. As reflected in the mean HAS-BLED scores, patients in India have a slightly higher risk of bleeding compared with the global average (SD): 1.5 (0.9) vs 1.4 (0.9) (P ¼ 0.002). Fig. 5a shows that Indian patients with highest risk of bleeding are more likely to receive AC ± AP than patients with no risk or low risk of bleeding. An increase in patients receiving NOAC therapy is shown for the highest risk patients (particularly HAS-BLED score of 4e9).
Antithrombotic treatment
Risk profiles and treatment patterns
Thromboembolic and bleeding profiles
INR readings and time in therapeutic range
A total of 368 INR readings were analyzed from 407 Indian patients receiving VKA; excluding those who had <3 INR readings. Globally, 158,121 INR readings were analyzed from a total of 20,182 Table S1 ).
Events rates at 1-year follow-up and clinical outcomes
Event rates per 100 person-years during the first year after diagnosis of AF in GARFIELD-AF are presented in Table 2 . Patients from India had markedly higher rates of all-cause mortality compared with all countries [7. Table S2 . Of all the cardiovascular causes of death, the most common were sudden or unwitnessed death (27.3%) and congestive heart failure (25%). Among the noncardiovascular causes of death, respiratory failure was the most frequent (26.3%). All stroke events of a known type were primary ischemic (0.79%)
Discussion
This is the first report of the GARFIELD-AF data of patients from India. The GARFIELD-AF describes an Indian population which is older than those described in previous registries from India. 2,9,10,15e18 None of the patients in the GARFIELD-AF registry had RVHD compared with 40%e60% of patients from other registries from India, 9, 10, 19, 20 thus representing an etiologically different form of AF than has been previously published. The use of antithrombotic therapy and its monitoring are major challenges for the health-care system in India because of poor INR monitoring and lack of compliance by patients. 9 In India, the most commonly prescribed antithrombotic for stroke prevention (regardless of stroke risk) was AP therapy alone, although AP is no longer recommended by Asian guidelines. 21 The European Society of Cardiology and National Institute for Health and Clinical Excellence guidelines also restrict the use of aspirin and other AP therapies for patients who refuse anticoagulation. 22 There was, however, a notable increase in VKA prescribing (and marked reduction in patients receiving no antithrombotic therapy) with increasing stroke risk. By contrast, NOACs were seldom prescribed, except for a slight increase in NOAC prescribing in patients with the highest risk of stroke. This could be due to the later approvals of NOACs in India. Possible economic limitations and other factors in India could also be affecting prescribing practices. NOACs are more expensive in comparison with VKA; however, in the long term, NOACs might prove to be the more cost-effective treatment choice compared with VKA treatment, 23 primarily because of lower monitoring costs and reduced numbers of patients with stroke and SE. 22 Practical guidelines on the management of stroke prevention in AF (SPAF) with NOACs in Asians, including Indians, have been published recently by Dalal et al 24 for the SPAF Academy India experts. Unlike many countries, the GARFIELD-AF registry has not observed any definitive increase in NOACs prescribing in India over time (as shown in Fig. 2 ). Of note, there are only 4000 cardiologists in India, and the ratio of physicians to cardiac patients is disproportionately low 25 compared with other countries. This could also be a factor influencing antithrombotic therapy prescription patterns in India. In India, the rate of all-cause mortality was higher than the global rate. This is due to the higher rate of cardiovascular deaths. The higher mortality was predominantly due to sudden death, CHF, myocardial infraction, and stroke. Comorbidities such as hypertension, CAD, and diabetes possibly resulted in higher mortality in AF, and these outcome results were comparable to the published results from the IHRS-AF registry. 
Conclusions
In conclusion, the global GARFIELD-AF registry continues to provide important information on the homogeneity and heterogeneity of baseline characteristics and treatment patterns in patients with newly diagnosed AF. Compared to the rest of the world, Indian patients are younger but associated with more diabetes and CAD. Patients with a higher stroke risk are likely to receive AC therapy with warfarin (compared with global average in the GARFIELD-AF registry), but tend to be underdosed as suggested by the INR. The registry provides evidence of higher mortality in newly diagnosed AF in India as compared with the global average in GARFIELD-AF. What is already known?
The combined prevalence of valvular and NVAF treated with vitamin K antagonists only in tertiary care centers of India.
What this study adds?
The prevalence of NVAF in the community and treatment with both vitamin K antagonists and NOACs. Treatment with NOACs in nonvalvular AF was missing in the past.
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